What is Esperite?
Esperite N.V., formerly Cryo-Save Group N.V., is a Dutch company specializing in regenerative and predictive medicine. Its operations span across four key segments: Stem Cell, The Cell Factory, Genoma, and Other. The company is involved in the collection, processing, and storage of adult stem cells from umbilical cord blood and tissue. Furthermore, Esperite offers advanced proteomics and genomics predictive medicine services, leveraging its proprietary technology for the clinical-grade production of autologous mesenchymal and stromal stem cells. Its Genoma segment develops AGAATA, a diagnostic system utilizing next-generation sequencing, enabling laboratories to conduct genetic analyses with Genoma's developed bioinformatics and methods. Esperite's product portfolio includes Tranquility, a non-invasive prenatal test, and Cryosave's whole genome sequencing and carrier screening tests, alongside its biobanking services for cord blood and tissue stem cells.
How much funding has Esperite raised?
Esperite has raised a total of $41M across 1 funding round:
Share Placement
$41M
Share Placement (2020): $41M, investors not publicly disclosed
What's next for Esperite?
The recent major strategic investment in Esperite N.V. signals a pivotal moment for the company, likely enabling accelerated growth and further development of its innovative regenerative and predictive medicine technologies. With a focus on expanding its international presence and enhancing its diagnostic and stem cell banking services, this capital infusion is expected to bolster its market position. The company's trajectory suggests a strong emphasis on scaling its clinical-grade stem cell production and advancing its genomic diagnostic solutions, positioning Esperite for significant advancements in the healthcare sector.
See full Esperite company page
